Humacyte is trading up 6.59% at $0.43 on October 27, 2026, with no confirmed catalyst for the rise. - The latest notable company news was positive V012 Phase 3 results presented at ASN Kidney Week, announced October 23; that news predates today’s rise and does not establish its cause. - The broader market is modestly higher, but supplied index moves are mixed and do not show a clear, same-direction explanation for Humacyte’s gain.